Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy

BACKGROUND Comorbidities are reportedly related to the survival of patients with non-small cell lung cancer (NSCLC). The purpose of this study was to explore the impact of comorbidity, assessed by the Charlson comorbidity index (CCI) and the simplified comorbidity scores (SCS) on clinical outcomes o...

Full description

Saved in:
Bibliographic Details
Published in:Medical science monitor 2020-09, Vol.26, p.e922576-e922576
Main Authors: Zeng, Xianghua, Zhu, Shicong, Xu, Cheng, Wang, Zhongyu, Su, Xingxing, Zeng, Dong, Long, Haixia, Zhu, Bo
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung - drug therapy
Clinical Research
Comorbidity
Female
Humans
Immune Checkpoint Inhibitors - therapeutic use
Lung Neoplasms - drug therapy
Male
Middle Aged
Progression-Free Survival
Retrospective Studies
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c381t-f83e431bc5427e6dd1834a389bcc3f9d227a451e8b1ba435a6473cddc81a0f423
cites
container_end_page e922576
container_issue
container_start_page e922576
container_title Medical science monitor
container_volume 26
creator Zeng, Xianghua
Zhu, Shicong
Xu, Cheng
Wang, Zhongyu
Su, Xingxing
Zeng, Dong
Long, Haixia
Zhu, Bo
description BACKGROUND Comorbidities are reportedly related to the survival of patients with non-small cell lung cancer (NSCLC). The purpose of this study was to explore the impact of comorbidity, assessed by the Charlson comorbidity index (CCI) and the simplified comorbidity scores (SCS) on clinical outcomes of patients with NSCLC treated with immune checkpoint inhibitors. MATERIAL AND METHODS Sixty-six patients with NSCLC who received programmed cell death protein 1 (PD1) inhibitors in our institution in the past 2 years were enrolled in this retrospective study. Data on comorbidity (CCI and SCS) and clinical outcomes, including progression-free survival (PFS), immunotherapy responses, and immunotherapy-related adverse events, were analyzed. RESULTS The disease control rate was obviously higher among patients in the CCI
doi_str_mv 10.12659/MSM.922576
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7496511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2440666026</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-f83e431bc5427e6dd1834a389bcc3f9d227a451e8b1ba435a6473cddc81a0f423</originalsourceid><addsrcrecordid>eNpVUclOwzAQtRCIpXDijnxEQgFvcZILUhVWqSwScLYc22mNGrvYDtC_J1BAcJkZzXt6szwA9jE6xoTn1cnNw81xRUhe8DWwjTmjGS1ytP6n3gI7MT4jREqO8k2wRUlZUcLpNng_b1ujEvQtrH3nQ2O1TUvoHbzrk_KdiZ_QvUzWuBThm00zONav0imj4a132UMn53NYmyFMejeF9ScU4JPTJky9HTpjl2x2f4bhddf1zqeZCXKx3AUbrZxHs_edR-Dp4vyxvsomd5fX9XiSKVrilLUlNYziRuWMFIZrjUvKJC2rRinaVpqQQrIcm7LBjWQ0l5wVVGmtSixRywgdgdOV7qJvOqPVcEaQc7EItpNhKby04j_i7ExM_asoWMVzjAeBw2-B4F96E5PobFTDvdIZ30dBGEOcczS8cwSOVlQVfIzBtL9jMBJfXonBK7HyamAf_N3sl_tjDv0AKXmQvQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2440666026</pqid></control><display><type>article</type><title>Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy</title><source>PubMed Central</source><creator>Zeng, Xianghua ; Zhu, Shicong ; Xu, Cheng ; Wang, Zhongyu ; Su, Xingxing ; Zeng, Dong ; Long, Haixia ; Zhu, Bo</creator><creatorcontrib>Zeng, Xianghua ; Zhu, Shicong ; Xu, Cheng ; Wang, Zhongyu ; Su, Xingxing ; Zeng, Dong ; Long, Haixia ; Zhu, Bo</creatorcontrib><description>BACKGROUND Comorbidities are reportedly related to the survival of patients with non-small cell lung cancer (NSCLC). The purpose of this study was to explore the impact of comorbidity, assessed by the Charlson comorbidity index (CCI) and the simplified comorbidity scores (SCS) on clinical outcomes of patients with NSCLC treated with immune checkpoint inhibitors. MATERIAL AND METHODS Sixty-six patients with NSCLC who received programmed cell death protein 1 (PD1) inhibitors in our institution in the past 2 years were enrolled in this retrospective study. Data on comorbidity (CCI and SCS) and clinical outcomes, including progression-free survival (PFS), immunotherapy responses, and immunotherapy-related adverse events, were analyzed. RESULTS The disease control rate was obviously higher among patients in the CCI &lt;1 group than the CCI ≥1 group (P&lt;0.001), but were similar between the SCS &lt;8 group and SCS ≥8 group (P=0.585). The median PFS in the CCI &lt;1 group was 271.0 days (95% CI: 214.3-327.7 days) compared with 232.0 days (95% CI: 66.2-397.8 days) for the CCI ≥1 group (P=0.0084). However, the median PFS showed no difference between the groups with SCS &lt;8 at 271.0 days (95% CI: 138.7-403.3 days) versus SCS ≥8 at 222.0 days (95% CI: 196.2-247.8 days), P=0.2106). The incidence of adverse events was similar among patients with high versus low comorbidity indexes (CCI: 35.8% versus 23.6%, P=0.286, respectively; and SCS: 28.0% versus 29.3%, respectively, P=0.912). CONCLUSIONS The comorbidity burden might be a predictor for survival in patients with NSCLC undergoing PD1 inhibitor immunotherapy.</description><identifier>ISSN: 1643-3750</identifier><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.922576</identifier><identifier>PMID: 32893263</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Clinical Research ; Comorbidity ; Female ; Humans ; Immune Checkpoint Inhibitors - therapeutic use ; Lung Neoplasms - drug therapy ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Medical science monitor, 2020-09, Vol.26, p.e922576-e922576</ispartof><rights>Med Sci Monit, 2020 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-f83e431bc5427e6dd1834a389bcc3f9d227a451e8b1ba435a6473cddc81a0f423</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496511/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496511/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32893263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zeng, Xianghua</creatorcontrib><creatorcontrib>Zhu, Shicong</creatorcontrib><creatorcontrib>Xu, Cheng</creatorcontrib><creatorcontrib>Wang, Zhongyu</creatorcontrib><creatorcontrib>Su, Xingxing</creatorcontrib><creatorcontrib>Zeng, Dong</creatorcontrib><creatorcontrib>Long, Haixia</creatorcontrib><creatorcontrib>Zhu, Bo</creatorcontrib><title>Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>BACKGROUND Comorbidities are reportedly related to the survival of patients with non-small cell lung cancer (NSCLC). The purpose of this study was to explore the impact of comorbidity, assessed by the Charlson comorbidity index (CCI) and the simplified comorbidity scores (SCS) on clinical outcomes of patients with NSCLC treated with immune checkpoint inhibitors. MATERIAL AND METHODS Sixty-six patients with NSCLC who received programmed cell death protein 1 (PD1) inhibitors in our institution in the past 2 years were enrolled in this retrospective study. Data on comorbidity (CCI and SCS) and clinical outcomes, including progression-free survival (PFS), immunotherapy responses, and immunotherapy-related adverse events, were analyzed. RESULTS The disease control rate was obviously higher among patients in the CCI &lt;1 group than the CCI ≥1 group (P&lt;0.001), but were similar between the SCS &lt;8 group and SCS ≥8 group (P=0.585). The median PFS in the CCI &lt;1 group was 271.0 days (95% CI: 214.3-327.7 days) compared with 232.0 days (95% CI: 66.2-397.8 days) for the CCI ≥1 group (P=0.0084). However, the median PFS showed no difference between the groups with SCS &lt;8 at 271.0 days (95% CI: 138.7-403.3 days) versus SCS ≥8 at 222.0 days (95% CI: 196.2-247.8 days), P=0.2106). The incidence of adverse events was similar among patients with high versus low comorbidity indexes (CCI: 35.8% versus 23.6%, P=0.286, respectively; and SCS: 28.0% versus 29.3%, respectively, P=0.912). CONCLUSIONS The comorbidity burden might be a predictor for survival in patients with NSCLC undergoing PD1 inhibitor immunotherapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Clinical Research</subject><subject>Comorbidity</subject><subject>Female</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Progression-Free Survival</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1643-3750</issn><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUclOwzAQtRCIpXDijnxEQgFvcZILUhVWqSwScLYc22mNGrvYDtC_J1BAcJkZzXt6szwA9jE6xoTn1cnNw81xRUhe8DWwjTmjGS1ytP6n3gI7MT4jREqO8k2wRUlZUcLpNng_b1ujEvQtrH3nQ2O1TUvoHbzrk_KdiZ_QvUzWuBThm00zONav0imj4a132UMn53NYmyFMejeF9ScU4JPTJky9HTpjl2x2f4bhddf1zqeZCXKx3AUbrZxHs_edR-Dp4vyxvsomd5fX9XiSKVrilLUlNYziRuWMFIZrjUvKJC2rRinaVpqQQrIcm7LBjWQ0l5wVVGmtSixRywgdgdOV7qJvOqPVcEaQc7EItpNhKby04j_i7ExM_asoWMVzjAeBw2-B4F96E5PobFTDvdIZ30dBGEOcczS8cwSOVlQVfIzBtL9jMBJfXonBK7HyamAf_N3sl_tjDv0AKXmQvQ</recordid><startdate>20200907</startdate><enddate>20200907</enddate><creator>Zeng, Xianghua</creator><creator>Zhu, Shicong</creator><creator>Xu, Cheng</creator><creator>Wang, Zhongyu</creator><creator>Su, Xingxing</creator><creator>Zeng, Dong</creator><creator>Long, Haixia</creator><creator>Zhu, Bo</creator><general>International Scientific Literature, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200907</creationdate><title>Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy</title><author>Zeng, Xianghua ; Zhu, Shicong ; Xu, Cheng ; Wang, Zhongyu ; Su, Xingxing ; Zeng, Dong ; Long, Haixia ; Zhu, Bo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-f83e431bc5427e6dd1834a389bcc3f9d227a451e8b1ba435a6473cddc81a0f423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Clinical Research</topic><topic>Comorbidity</topic><topic>Female</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Progression-Free Survival</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Zeng, Xianghua</creatorcontrib><creatorcontrib>Zhu, Shicong</creatorcontrib><creatorcontrib>Xu, Cheng</creatorcontrib><creatorcontrib>Wang, Zhongyu</creatorcontrib><creatorcontrib>Su, Xingxing</creatorcontrib><creatorcontrib>Zeng, Dong</creatorcontrib><creatorcontrib>Long, Haixia</creatorcontrib><creatorcontrib>Zhu, Bo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zeng, Xianghua</au><au>Zhu, Shicong</au><au>Xu, Cheng</au><au>Wang, Zhongyu</au><au>Su, Xingxing</au><au>Zeng, Dong</au><au>Long, Haixia</au><au>Zhu, Bo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2020-09-07</date><risdate>2020</risdate><volume>26</volume><spage>e922576</spage><epage>e922576</epage><pages>e922576-e922576</pages><issn>1643-3750</issn><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>BACKGROUND Comorbidities are reportedly related to the survival of patients with non-small cell lung cancer (NSCLC). The purpose of this study was to explore the impact of comorbidity, assessed by the Charlson comorbidity index (CCI) and the simplified comorbidity scores (SCS) on clinical outcomes of patients with NSCLC treated with immune checkpoint inhibitors. MATERIAL AND METHODS Sixty-six patients with NSCLC who received programmed cell death protein 1 (PD1) inhibitors in our institution in the past 2 years were enrolled in this retrospective study. Data on comorbidity (CCI and SCS) and clinical outcomes, including progression-free survival (PFS), immunotherapy responses, and immunotherapy-related adverse events, were analyzed. RESULTS The disease control rate was obviously higher among patients in the CCI &lt;1 group than the CCI ≥1 group (P&lt;0.001), but were similar between the SCS &lt;8 group and SCS ≥8 group (P=0.585). The median PFS in the CCI &lt;1 group was 271.0 days (95% CI: 214.3-327.7 days) compared with 232.0 days (95% CI: 66.2-397.8 days) for the CCI ≥1 group (P=0.0084). However, the median PFS showed no difference between the groups with SCS &lt;8 at 271.0 days (95% CI: 138.7-403.3 days) versus SCS ≥8 at 222.0 days (95% CI: 196.2-247.8 days), P=0.2106). The incidence of adverse events was similar among patients with high versus low comorbidity indexes (CCI: 35.8% versus 23.6%, P=0.286, respectively; and SCS: 28.0% versus 29.3%, respectively, P=0.912). CONCLUSIONS The comorbidity burden might be a predictor for survival in patients with NSCLC undergoing PD1 inhibitor immunotherapy.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>32893263</pmid><doi>10.12659/MSM.922576</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1643-3750
ispartof Medical science monitor, 2020-09, Vol.26, p.e922576-e922576
issn 1643-3750
1234-1010
1643-3750
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7496511
source PubMed Central
subjects Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung - drug therapy
Clinical Research
Comorbidity
Female
Humans
Immune Checkpoint Inhibitors - therapeutic use
Lung Neoplasms - drug therapy
Male
Middle Aged
Progression-Free Survival
Retrospective Studies
Treatment Outcome
title Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T17%3A18%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Comorbidity%20on%20Outcomes%20of%20Patients%20with%20Advanced%20Non-Small%20Cell%20Lung%20Cancer%20Undergoing%20Anti-PD1%20Immunotherapy&rft.jtitle=Medical%20science%20monitor&rft.au=Zeng,%20Xianghua&rft.date=2020-09-07&rft.volume=26&rft.spage=e922576&rft.epage=e922576&rft.pages=e922576-e922576&rft.issn=1643-3750&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.922576&rft_dat=%3Cproquest_pubme%3E2440666026%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c381t-f83e431bc5427e6dd1834a389bcc3f9d227a451e8b1ba435a6473cddc81a0f423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2440666026&rft_id=info:pmid/32893263&rfr_iscdi=true